Released: 17/07/2018 – 17:28 GMT
RNS Number: 9470U
Castelvecchio Pascoli (Lucca, Italy), 17 July 2018 – Kedrion S.p.A., a biopharmaceutical company that specializes in the development, production and distribution of plasma‐derived therapies and in the collection of plasma, announces that the Extraordinary Meeting of Shareholders held on 12 July 2018 approved the amendment of the Company’s bylaws.
The bylaws are available here.
For further information, please write to [email protected]
Kedrion is a leading biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders.
The Company operates through a fully integrated business model from the collection of plasma in its own centers in the United States, Hungary and Germany to fractionation and production in its manufacturing facilities located in Italy, Hungary and the United States.
Headquartered in Castelvecchio Pascoli (Italy), Kedrion has over 2,400 employees and a commercial presence in approximately 100 countries worldwide.
Kedrion places a high value on the welfare of those who benefit from its products, as well as on the people and the communities it serves.
Additional information about Kedrion can be found at kedrion.com